| 血小板与淋巴细胞比值预测三阴性乳腺癌临床预后及与免疫球蛋白表达的关系 |
| |
| 引用本文： | 李伟杰,白 洁,谢贤鑫,王 聪,姜大庆.血小板与淋巴细胞比值预测三阴性乳腺癌临床预后及与免疫球蛋白表达的关系[J].现代肿瘤医学,2020,0(8):1293-1297. |
| |
| 作者姓名： | 李伟杰 白 洁 谢贤鑫 王 聪 姜大庆 |
| |
| 作者单位： | 中国医科大学肿瘤医院 辽宁省肿瘤医院乳腺外科，辽宁 沈阳 110042 |
| |
| 基金项目： | 辽宁省自然科学基金（编号:2019-ZD-0597） |
| |
| 摘 要： | 目的:探讨血小板与淋巴细胞比值（platelet to lymphocyte ratio，PLR）对三阴性乳腺癌的临床预后影响及与免疫球蛋白表达的关系。方法:回顾性分析2006年1月至2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan-Meier和log-rank方法。结果:PLR是三阴性乳腺癌的独立预后因素，最佳临界值为155.00。PLR＜155.00组，术后中位DFS为35.51月，中位OS为55.24月；PLR≥155.00组，术后中位DFS为25.07月，中位OS为35.17月。两组术后DFS和OS比较，差异具有统计学意义（P＜0.05）。结论:PLR是三阴性乳腺癌的独立预后因素，具有重复性强、非侵袭性、方便实用等特性，可用于预测三阴性乳腺癌临床预后。
|
| 关 键 词： | 三阴性乳腺癌 血小板与淋巴细胞比值 免疫球蛋白 无病生存期 总生存期 |
Platelet to lymphocyte ratio (PLR) in patients with triple negative breast cancer and its relationship with immunoglobulins expression |
| |
| Li Weijie,Bai Jie,Xie Xianxin,Wang Cong,Jiang Daqing.Platelet to lymphocyte ratio (PLR) in patients with triple negative breast cancer and its relationship with immunoglobulins expression[J].Journal of Modern Oncology,2020,0(8):1293-1297. |
| |
| Authors: | Li Weijie Bai Jie Xie Xianxin Wang Cong Jiang Daqing |
| |
| Affiliation: | Department of Breast Surgery,Cancer Hospital of China Medical University,Liaoning Cancer Hospital & Institute,Liaoning Shenyang 110042,China. |
| |
| Abstract: | Objective:To explore the potential prognostic significance of platelet to lymphocyte ratio (PLR) in patients with triple negative breast cancer (TNBC) and its relationship with immunoglobulins expression.Methods:134 patients with TNBC were enrolled in the present study in our hospital from January 2006 to December 2012.The univariate and multivariate Cox's proportional hazards regression model was used to evaluate the independent prognostic factors.The survival time was analyzed by the Kaplan-Meier plots and log-rank test.Results:PLR was the independent prognostic factor in TNBC,and the optimal cutoff value was 155.00.In PLR＜155.00 group,the median disease free survival (DFS) was 35.51 months,and the median overall survival (OS) was 55.24 months,respectively.In PLR≥2.64 group,the median DFS was 25.07 months,and the median overall survival (OS) was 35.17 months,respectively.The median DFS and OS time for patients with low NLR were longer than for those with high NLR by using log-rank methods (P＜0.05).Conclusion:PLR is the independent prognostic factor in TNBC,and has the advantage of reproducible,noninvasive,and convenient.It is a good and effective predictor of prognosis in patients with TNBC. |
| |
| Keywords: | triple negative breast cancer platelet to lymphocyte ratio immunoglobulins disease free survival overall survival |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
